OncoSec Medical Inc (ONCSQ)

[lasers]

OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York CityKey Opinion Leaders in Melanoma and Company Representatives to Discuss Unmet Needs in Immunotherapy
PR NEWSWIRE 6:01 AM ET 2/24/2017
Symbol Last Price Change
ONCS 1.42down 0 (0%)
QUOTES AS OF 03:59:58 PM ET 02/23/2017
SAN DIEGO , Feb. 24, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") , a company developing DNA-based intratumoral cancer immunotherapies, will host a Key Opinion Leader event to highlight new clinical data that will be featured as an oral and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company's melanoma development plan. The KOL event will be held in-person and via live webcast on Tuesday, February 28 at 12:00 PM EST / 9:00 AM PST at the Lotte New York Palace Hotel in New York City.

The KOL event will feature a presentation by Alain Algazi, MD, skin cancer specialist in the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center, who will discuss the latest clinical data from the Phase II Investigator Sponsored Trial led by the University of California, San Francisco. This trial is evaluating the combination of OncoSec's investigational therapy, ImmunoPulse® IL-12, and the approved anti-PD-1 therapy, pembrolizumab in patients with unresectable metastatic melanoma. Additionally, Dr. Algazi will address the current treatment landscape for melanoma patients and describe where there is still an unmet medical need for new treatment options.

Sharron Gargosky, PhD, OncoSec's Chief Clinical and Regulatory Officer, and Chris Twitty, PhD, OncoSec's Director of Clinical Science, will provide an overview of the Company's ongoing clinical research with ImmunoPulse® IL-12 in patients with advanced melanoma who are anti-PD-1 non- responders. Their discussion will focus on the target patient population and the Company's clinical strategy moving forward.

Following the presentation, all presenters will be available for questions. This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend in-person, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at [e-mail].

To view the live webcast, please access the following link at the time of presentation: http://lifesci.rampard.com/20170228/reg.jsp. An archived version of the webcast will be available on OncoSec's website: http://ir.oncosec.com/events-presentations.